CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

AstraZeneca's mRNA deal with China's CanSino comes a year after the British pharma ended a cardiovascular and oncology collaboration with Moderna.

Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two that AstraZeneca dumped last year.. The Big ...

Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

AstraZeneca said on Wednesday a review of real-world data showed its COVID-19 vaccine provided equally effective protection against hospitalisation and death after two doses as with current mRNA ...

Several mRNA vaccines are in the works that will tackle everything from ovarian, ... In the case of COVID, “the Oxford-Astrazeneca vaccine trials (of 2020) recruited 30,000 in less than a year.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

In 2022, mRNA might be best known for making the covid vaccine possible. However, it’s in fact a novel approach for drug discovery. All life forms on earth share the following structure: They ...

“AstraZeneca is very good, but the mRNA products… are better,” Head said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest Covid variants.

“AstraZeneca is very good, but the mRNA products… are better,” he said. “They have higher effectiveness and the mRNA platforms are more easily adapted towards the latest COVID variants.